ISPE announces Thomas Hartman as CEO and president
Mike EdwardsPeople in Process GSK
The International Society for Pharmaceutical Engineering (ISPE) of North Bethesda, MD, has announced that Thomas Hartman has been appointed as CEO and president. Hartman has a long history in the pharmaceutical industry, rising to the role of VP of GMP Operations, Biopharm CMC, for GlaxoSmithKline (GSK).
“The recent pandemic highlights the need for effective platforms for collaboration to resolve complex industry challenges,” according to Hartman. “ISPE and its more than 18,000 Members are positioned well to support the entire pharmaceutical industry in the development and manufacturing of transformational medicines for patients.
“It is a true privilege to be given the opportunity to play a significant role in the industry, and I look forward to working with the ISPE board, staff, worldwide membership, and all industry stakeholders to further advance and build on ISPE’s success over the past 40 years.”
Prior to joining GlaxoSmithKline in 2001, Hartman held multiple engineering and operations roles with a major US-based chemical manufacturer, including a five-year expatriate role in the Netherlands and the UK, culminating with responsibilities as head of engineering at a large chemical facility. In his career, Hartman has successfully conducted business in multiple countries including the US, UK, East/West Europe, China, Korea, Singapore, India, and Mexico.
Print this page